# Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

> **NCT03143049** · PHASE3 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 120 (estimated)

## Conditions studied

- Relapse Multiple Myeloma

## Interventions

- **DRUG:** PCD
- **DRUG:** PD

## Key facts

- **NCT ID:** NCT03143049
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-13
- **Primary completion:** 2018-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-11-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03143049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03143049, "Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03143049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*